Dendreon is committed to developing innovative cancer therapies. The company’s initiatives are intended to address an unmet medical need, improve the lives of patients and provide effective therapies with a favorable safety and tolerability profile.

Except for historical information contained herein, the information in this site contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects. Information on the factors and risks that could affect Dendreon's business, financial condition, and results of operations are contained in Dendreon’s public disclosure filings with the U.S. Securities and Exchange Commission, which are available at

Dendreon’s research and development program continues to explore the application of autologous cellular immunotherapies (ACI) and other immune approaches to the potential treatment of a variety of cancers.